Analysts Expect Seres Therapeutics Inc (NASDAQ:MCRB) to Post -$0.26 EPS

Equities research analysts expect Seres Therapeutics Inc (NASDAQ:MCRB) to post earnings per share of ($0.26) for the current quarter, according to Zacks. Three analysts have issued estimates for Seres Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.22) and the lowest estimate coming in at ($0.30). Seres Therapeutics posted earnings of ($0.52) per share in the same quarter last year, which indicates a positive year-over-year growth rate of 50%. The firm is expected to issue its next quarterly earnings results on Wednesday, March 4th.

According to Zacks, analysts expect that Seres Therapeutics will report full year earnings of ($1.42) per share for the current year, with EPS estimates ranging from ($2.04) to ($1.20). For the next year, analysts expect that the business will post earnings of ($0.87) per share, with EPS estimates ranging from ($1.26) to ($0.51). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research analysts that cover Seres Therapeutics.

Seres Therapeutics (NASDAQ:MCRB) last posted its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported ($0.23) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.03. The firm had revenue of $7.03 million during the quarter, compared to analyst estimates of $6.69 million.

Several analysts recently issued reports on MCRB shares. Zacks Investment Research downgraded Seres Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, October 29th. HC Wainwright restated a “buy” rating and set a $8.00 price objective on shares of Seres Therapeutics in a research report on Thursday, November 21st. Cowen reissued a “buy” rating on shares of Seres Therapeutics in a research report on Monday, November 4th. Chardan Capital restated a “buy” rating on shares of Seres Therapeutics in a report on Thursday, September 19th. Finally, BidaskClub upgraded shares of Seres Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, November 7th. Three investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Seres Therapeutics currently has an average rating of “Buy” and an average price target of $7.75.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Tower Research Capital LLC TRC grew its stake in Seres Therapeutics by 3,656.7% during the 2nd quarter. Tower Research Capital LLC TRC now owns 8,678 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 8,447 shares during the last quarter. Aries Wealth Management purchased a new stake in shares of Seres Therapeutics during the 3rd quarter worth approximately $31,000. SG Americas Securities LLC purchased a new stake in shares of Seres Therapeutics during the 2nd quarter worth approximately $34,000. Parametric Portfolio Associates LLC acquired a new stake in shares of Seres Therapeutics in the 2nd quarter worth approximately $42,000. Finally, Voya Investment Management LLC grew its holdings in shares of Seres Therapeutics by 35.1% in the 3rd quarter. Voya Investment Management LLC now owns 13,670 shares of the biotechnology company’s stock worth $55,000 after acquiring an additional 3,555 shares during the period. Hedge funds and other institutional investors own 91.91% of the company’s stock.

Shares of NASDAQ MCRB traded down $0.10 during mid-day trading on Wednesday, hitting $3.65. The company had a trading volume of 2,972 shares, compared to its average volume of 182,598. The firm has a 50-day simple moving average of $3.67 and a two-hundred day simple moving average of $3.39. The company has a market capitalization of $276.55 million, a PE ratio of -1.51 and a beta of 1.82. Seres Therapeutics has a one year low of $2.02 and a one year high of $8.39.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc, a microbiome therapeutics platform company, engages in developing biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome. The company's advanced program is the SER-109, which is in Phase III clinical development for reducing recurrent clostridium difficile infection (CDI).

Recommended Story: What factors cause inflation to rise?

Get a free copy of the Zacks research report on Seres Therapeutics (MCRB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Seres Therapeutics (NASDAQ:MCRB)

Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.